Literature DB >> 1436965

Intraoperative application of 5-fluorouracil during trabeculectomy.

P J Dietze1, R M Feldman, R L Gross.   

Abstract

We report the preliminary results of the first 20 consecutive cases in which the antimetabolite 5-fluorouracil (5-FU) was applied directly beneath the conjunctival flap during trabeculectomy in high-risk patients. Seventeen were considered early successes, with 3-month postoperative intraocular pressures less than 21 mmHg, representing at least a 20% decrease from preoperative values. Successful blebs were pale, with conjunctival microcysts and without significant vascularization over the trabeculectomy site, similar to the appearance of blebs in eyes administered postoperative subconjunctival injections of 5-FU. There were no cases of corneal epithelial defects, and no eyes had lost more than one line of preoperative vision at the time of last follow up. Although the longer term efficacy of this method is unknown, these results suggest that it may represent a safe and effective alternative for administering 5-FU.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436965

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  4 in total

1.  Collagen type I and III synthesis by Tenon's capsule fibroblasts in culture: individual patient characteristics and response to mitomycin C, 5-fluorouracil, and ascorbic acid.

Authors:  R L Gross
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Comparison of 90-s versus 5-min intraoperative 5-fluorouracil in trabeculectomy.

Authors:  Andrea Zarkovic; Kent Chow; Justin S Mora
Journal:  Int Ophthalmol       Date:  2009-01-10       Impact factor: 2.031

Review 3.  Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans.

Authors:  Y Lachkar; M Leyland; P Bloom; C Migdal
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

4.  Bleb morphology and histology in a rabbit model of glaucoma filtration surgery using Ozurdex® or mitomycin-C.

Authors:  Jeffrey R SooHoo; Leonard K Seibold; Ashley E Laing; Malik Y Kahook
Journal:  Mol Vis       Date:  2012-03-26       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.